118 related articles for article (PubMed ID: 36717270)
21. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
25. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
[TBL] [Abstract][Full Text] [Related]
26. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
[TBL] [Abstract][Full Text] [Related]
27. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects.
Cui X; Chen X; Pognan N; Sengupta T; Rahmanzadeh G; Kornberger R; Giovannini M
J Clin Pharmacol; 2023 Feb; 63(2):228-238. PubMed ID: 36087217
[TBL] [Abstract][Full Text] [Related]
29. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
30. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects.
Asari K; Ishii M; Yoshitsugu H; Wakana A; Fancourt C; Yoon E; Furihata K; McCrea JB; Stoch SA; Iwamoto M
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):938-948. PubMed ID: 35238179
[TBL] [Abstract][Full Text] [Related]
32. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
[TBL] [Abstract][Full Text] [Related]
33. A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.
Trivedi A; Mather O; Vega S; Hutton S; Hellawell J; Lee E
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):849-856. PubMed ID: 35247290
[TBL] [Abstract][Full Text] [Related]
34. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam.
Ren S; Vishwanathan K; Cantarini M; Frewer P; Hara I; Scarfe G; Burke W; Schalkwijk S; Li Y; Han D; Goldwater R
Br J Clin Pharmacol; 2022 Feb; 88(2):655-668. PubMed ID: 34322894
[TBL] [Abstract][Full Text] [Related]
36. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study.
Huang Y; Jia Y; Chen X; Wang C; Wang Y; Wang M; Wu P; Shen J
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):1005-1013. PubMed ID: 38053514
[TBL] [Abstract][Full Text] [Related]
37. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
[TBL] [Abstract][Full Text] [Related]
38. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
[TBL] [Abstract][Full Text] [Related]
39. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
[TBL] [Abstract][Full Text] [Related]
40. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
